

ZEPOSIA (ozanimod)

Preferred MS product: Zeposia
Zeposia is non-preferred for UC

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Relapsing Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
 - a. **NO** concurrent use with other MS disease modifying agents
2. Moderately to severely active Ulcerative Colitis (UC)
 - a. Inadequate response, intolerance, or contraindication to at least **ONE** conventional therapy option (see Appendix 1)
 - b. **NOT** to be used in combination with a biologic DMARD or targeted synthetic DMARD for UC (e.g., Entyvio, Humira, Simponi, Stelara, Xeljanz)
 - c. Patient **MUST** have tried the preferred product(s) (see Appendix 2) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

AND ALL of the following:

1. Baseline evaluations of **ALL** of the following have been done or will be done prior to starting therapy with Zeposia:
 - a. Complete blood count (CBC), including lymphocyte count
 - b. Electrocardiogram (ECG)
 - c. Liver function tests (LFTs)
2. Heart rate \geq 55 bpm
3. **NO** history (within the last 6 months) of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
4. **NO** presence of Mobitz Type II second-degree or third degree AV block, sick sinus syndrome, or sino-atrial block, unless patient has a pacemaker
5. **NO** significant QTc prolongation (QTcF $>$ 450 msec in males, $>$ 470 msec in females)

ZEPOSIA (ozanimod)

Preferred MS product: Zeposia
Zeposia is non-preferred for UC

6. **NO** severe untreated sleep apnea
7. Patients with a history of uveitis and/or diabetes **ONLY**: will have an ophthalmic evaluation of fundus, including the macula, prior to initiation of therapy
8. **NOT** given concurrently with live vaccines

Prior - Approval Limits

Quantity 90 capsules per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Relapsing Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
 - a. **NO** concurrent use with other MS disease modifying agents
2. Ulcerative Colitis (UC)
 - a. Condition has improved or stabilized
 - b. **NOT** to be used in combination with a biologic DMARD or targeted synthetic DMARD for UC (e.g., Entyvio, Humira, Simponi, Stelara, Xeljanz)
 - c. Patient **MUST** have tried the preferred product(s) (see Appendix 2) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

AND ALL of the following:

1. Heart rate \geq 55 bpm
2. **NO** history (within the last 6 months) of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.
3. **NO** presence of Mobitz Type II second-degree or third degree AV block, sick sinus syndrome, or sino-atrial block, unless patient has a pacemaker
4. **NO** significant QTc prolongation (QTcF $>$ 450 msec in males, $>$ 470 msec

ZEPOSIA (ozanimod)

Preferred MS product: Zeposia
Zeposia is non-preferred for UC

in females)

5. **NO** severe untreated sleep apnea
6. **NOT** given concurrently with live vaccines

Prior - Approval *Renewal* Limits

Same as above

Appendix 1 – List of Conventional Therapies

Conventional Therapy Options	
1. Mild to moderate disease – induction of remission:	<ol style="list-style-type: none"> a. Oral budesonide, oral mesalamine b. Alternatives: metronidazole, ciprofloxacin
2. Mild to moderate disease – maintenance of remission:	<ol style="list-style-type: none"> a. Azathioprine, mercaptopurine b. Alternatives: oral budesonide, methotrexate intramuscularly (IM)
3. Moderate to severe disease – induction of remission:	<ol style="list-style-type: none"> a. Prednisone, methylprednisolone intravenously (IV) b. Alternatives: methotrexate IM
4. Moderate to severe disease – maintenance of remission:	<ol style="list-style-type: none"> a. Azathioprine, mercaptopurine b. Alternative: methotrexate IM
5. Perianal and fistulizing disease – induction of remission	<ol style="list-style-type: none"> c. Metronidazole ± ciprofloxacin
6. Perianal and fistulizing disease – maintenance of remission	<ol style="list-style-type: none"> d. Azathioprine, mercaptopurine e. Alternative: methotrexate IM

Appendix 2 - List of Preferred Products

Diagnosis	Standard Option/Basic Option Preferred Products	Blue Focus Preferred Products
Ulcerative colitis (UC)	<p>*must try TWO preferred products:</p> <p>Humira Rinvoq Skyrizi Stelara (SC) Tremfya</p>	Humira